Andrea Lobo, PhD,  science writer—

Lumina Imaging has partnered with the Multiple Sclerosis Association of America (MSAA) to provide affordable brain and spinal cord MRI scans to multiple sclerosis (MS) patients. The partnership makes Lumina the preferred provider for the MSAA’s MRI Access Program in northeast Ohio. The program is designed…

Metabolon and Cardiff University are partnering to discover new biomarkers that could help better understand disease mechanisms and develop new treatments for multiple sclerosis (MS). The project leverages Metabolon’s expertise in metabolomics, a field of research that measures all products of metabolism, called metabolites, that are made…

Treatment with rituximab, an approved CD20 inhibitor that’s sometimes used off-label for multiple sclerosis (MS), was found to adequately control the neurodegenerative disease in patients diagnosed during childhood or adolescence, a new study showed. The therapy, given by  infusion into the bloodstream, was generally safe and significantly reduced…

Researchers at Stanford University have partnered with Kyverna Therapeutics to conduct an investigator-initiated clinical trial of the company’s cell-based therapy, KYV-101, in people with progressive forms of multiple sclerosis (MS) without relapses. The open-label Phase 1 trial (NCT06138132) will take place at the Stanford Multiple Sclerosis…

TG Therapeutics has secured three additional U.S. patents for Briumvi (ublituximab-xiiy), an anti-CD20 antibody that’s been approved to treat relapsing forms of multiple sclerosis (MS). Issued by the U.S. Patent and Trademark Office, the patent numbers 11,807,689; 11,814,439; and 11,884,740 specifically cover the composition and…

Briumvi (ublituximab-xiiy), an approved treatment for relapsing forms of multiple sclerosis (MS), is now available to patients in Europe, where it’s being marketed by Neuraxpharm. The infusion therapy, developed by TG Therapeutics, was first launched in Germany, with additional rollouts following in other European countries. Under…

Sweden has a consistently high incidence and prevalence of pediatric-onset multiple sclerosis (PoMS), according to a recently published study. Incidence measures the number of new cases identified during a certain period, while prevalence measures the proportion of people in the population with the condition. Data show the disease is…

More women with multiple sclerosis (MS) got pregnant in recent years, probably linked to a significantly higher use of disease-modifying therapies (DMTs) during pregnancy, according to a nationwide study in France. DMTs are a type of treatment that can alter MS course, by reducing the risk of relapses,…

Sudo Biosciences has secured an additional $30 million in funding to support the development of two TYK2 inhibitor therapies for multiple sclerosis (MS) and other neurological and skin conditions — and now is aiming to launch clinical trials later this year. With a second close of its Series…

Some people with secondary progressive multiple sclerosis (SPMS) using Mayzent (siponimod) show a severe drop in their number of lymphocytes, a condition known as lymphopenia, shortly after starting treatment, a report on its real-world use in the U.K. found. Lymphocytes are white blood cells that help the immune…

Treatment with Zeposia (ozanimod) during early pregnancy may be safe for women with multiple sclerosis (MS), or inflammatory bowel diseases,  a recent study suggests. Specifically, receiving the treatment during the first trimester of pregnancy didn’t increase the incidence of fetal malformations or…

Gender and age at the onset of disease don’t seem to have a clinically relevant impact on disability progression in people with primary progressive multiple sclerosis (PPMS), according to a recent study in Argentina. Disease progression, based on the Expanded Disability Status…

Foods that promote inflammation appear to contribute to the development over time of depression and anxiety in people with multiple sclerosis (MS), a study that followed patients for 10 years reports. A pro-inflammatory diet, however, was not linked to fatigue, a common MS symptom. “If the relationship with…

People with multiple sclerosis (MS) utilize more healthcare resources a year before their MS diagnosis, suggesting this may be a period of prodromal MS, when patients start having unspecific and mild MS symptoms. These might include mild cognitive issues, skin problems, and anemia, when the body doesn’t have…

The U.S. Food and Drug Administration (FDA) has granted fast track status to KYV-101, Kyverna Therapeutics’ cell-based therapy candidate for people with progressive forms of multiple sclerosis (MS) that are treatment-resistant. The FDA designation is intended to accelerate the development of therapies that aim to address unmet medical…

A research team at the Kessler Foundation has received a $39,994 grant from the Consortium of Multiple Sclerosis Centers (CMSC) to investigate whether combining aerobic cycling with virtual reality can improve cognitive function in people with multiple sclerosis (MS). A key focus of the study will be to…

Fampyra (fampridine), an approved oral treatment to improve the walking abilities of adults with multiple sclerosis (MS), soon will be sold by Acorda Therapeutics worldwide. The announcement follows the decision by Biogen to terminate a licensing agreement that gave it global development and marketing rights…

Mitochon Pharmaceuticals is launching a pilot clinical trial to evaluate MP101, its treatment candidate for improving mitochondrial function, in people with multiple sclerosis (MS) and other neurodegenerative diseases. The announcement follows the trial’s clearance by the European Medicines Agency (EMA), which enables Mitochon to begin enrolling patients with…

Monte Rosa Therapeutics is planning to initiate a Phase 1 clinical trial to test MRT-6160, its investigational therapy for multiple sclerosis (MS) and other autoimmune diseases, by mid-2024. The trial will follow the submission of an investigational new drug (IND) application, a formal request to U.S. regulatory authorities…

Sending SMS text messages to people with multiple sclerosis (MS) — with tips for fatigue self-management and to regularly check in on them — may be a feasible, acceptable, and engaging tool to help these patients manage disease-related fatigue, according to a pilot study. The findings also showed some…

Remote coaching sessions to support the mental and emotional health of informal multiple sclerosis (MS) caregivers, coupled with online information, showed significant benefits after four months, according to a pilot study. These coaching sessions — known as psychoeducation — focused on information, support, and strategies for caring and planning…

Ocrevus (ocrelizumab) did not significantly reduce the number or volume of inflammatory lesions in the meninges in people with multiple sclerosis (MS), according to a recent pilot study. While inflammation in the meninges, the protective membranes that surround the brain and spinal cord, is thought to be driven…

MediciNova announced the approval of a European patent covering the use of ibudilast (MN-166) in combination with interferon-beta medications to treat progressive forms of multiple sclerosis (MS) — primary progressive MS (PPMS) and secondary progressive MS (SPMS) — in patients previously using an interferon-beta.

Enrollment is nearly complete in a clinical trial of the Scone neuromodulation device in treating neurogenic, or overactive, bladder due to multiple sclerosis (MS), stroke, or spinal cord injury, SpineX, its developer, announced. Currently, 95 adult patients (more than 80% of planned total), ages 18 to…

The U.S. Food and Drug Administration (FDA) has placed a partial hold on Genentech’s ongoing Phase 3 clinical trials testing fenebrutinib for the treatment of relapsing and primary progressive forms of multiple sclerosis (MS). The decision was based on two cases of patients who experienced elevations in their…

Higher blood levels of macrophage migration inhibitory factor (MIF), a molecule involved in inflammation, may predict a faster rate of brain shrinkage, or atrophy, in people with primary progressive multiple sclerosis (PPMS). That’s according to a new analysis of data from the SPRINT-MS Phase 2 trial (NCT01982942) that…

EBV-001, a vaccine candidate being developed by EBViously to target the Epstein-Barr virus (EBV), triggered the production of potent antibodies against the virus in mice, and blood samples from these animals prevented EBV infection in lab-grown human cells. That’s according to new data presented by the company, which is…

Tiziana Life Sciences has dosed four new participants in an expanded access program investigating its foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS), the company announced. A total of 10 SPMS patients are now being followed outside of clinical trials in foralumab’s expanded…

The U.S. Food and Drug Administration (FDA) has cleared BrainSpec Core, a platform that performs non-invasive measurements of brain chemistry, for use in diagnosing some of the most common diseases that affect the brain, including multiple sclerosis (MS). Developed by BrainSpec, the platform uses magnetic resonance spectroscopy (MRS)…

Certain clinical attributes of disease-modifying therapies (DMTs), such as safety and the medication’s impact on risk of relapse and disability progression, are considered important by healthcare providers in selecting the appropriate treatment for people with multiple sclerosis (MS), according to a new survey study. However, a study experiment also…